Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OLX10010
- Development stage
- Phase 2
- Lead developer
- Olix Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
OLX10010 is an investigational asymmetric small interfering RNA (siRNA) duplex with a cell-penetrating moiety attached to the 3' end of the sense strand, classified as a cell-penetrating asymmetric siRNA (cp-asiRNA). It specifically targets human connective tissue growth factor (CTGF), also known as CCN2, which plays a key role in the development of hypertrophic scars and other fibrotic diseases. By binding to CTGF mRNA, OLX10010 induces its degradation via RNA interference mechanisms, thereby reducing CTGF protein expression. This mechanism aims to prevent or reduce hypertrophic scar formation following surgery. The drug is administered intradermally and has shown significant improvement in scar appearance compared to placebo in Phase 2a clinical trials. Developed by OliX Pharmaceuticals, OLX10010 is being evaluated for safety and efficacy primarily for hypertrophic scar treatment[1][3][4][5].
- Other names
- OLX 101AOLX101AOLX-101A
Beyond the preview
Go deeper on OLX10010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OLX10010.